Trimetazidine dihydrochloride

Research use only, not for human use.

Trimetazidine dihydrochloride is a drug for angina pectoris. Trimetazidine is the first cytoprotective anti-ischemic agent.

Trimetazidine dihydrochloride is a drug for angina pectoris. Trimetazidine is the first cytoprotective anti-ischemic agent , which improves myocardial glucose utilization through inhibition of fatty acid metabolism.(In Vitro):Trimetazidine (1 μM-100 μM; 24 hours; HUVECs) could enhance the viability of the injured HUVECs induces by oxidation in a certain dose-dependent manner.(In Vivo):Trimetazidine (5-20 mg/kg; oral administration; 1 hour; Swiss albino male mice) in 10 mg/kg and 20 mg/kg doses significantly raises the seizure-threshold current in the increasing current electroshock seizure (ICES) test in the mice.

Trimetazidine (1 μM-100 μM; 24 hours; HUVECs) could enhance the viability of the injured HUVECs induces by oxidation in a certain dose-dependent manner. Cell Viability Assay Cell Line:Human umbilical vein endothelial cells (HUVECs)Concentration:1 μM, 10 μM, 100 μM Incubation Time:24 hours Result:Enhanced the viability of the injured HUVECs induced by oxidation.

Trimetazidine (5-20 mg/kg; oral administration; 1 hour; Swiss albino male mice) in 10 mg/kg and 20 mg/kg doses significantly raises the seizure-threshold current in the increasing current electroshock seizure (ICES) test in the mice. Animal Model:Swiss albino male mice (24-35 g)Dosage:5 mg/kg, 10 mg/kg and 20 mg/kg;10 mL/kg body weight Administration:Oral administration; 1 hour Result:In 10 mg/kg and 20 mg/kg doses significantly raised the seizure-threshold current in the ICES test.

Trimetazidine Dihydrochloride

Metabolic Enzyme/Protease

Fatty Acid Synthase

mitochondrial long-chain 3-ketoacyl thiolase

Cardiovascular Disease

——

13171-25-0

339.26

C14H22N2O3·2HCl

>98% (HPLC)

Water: 10 mM

COC1=CC=C(CN2CCNCC2)C(OC)=C1OC.[H]Cl.[H]Cl

1-[(2,3,4-Trimethoxyphenyl)methyl]piperazine dihydrochloride

(-20℃)

With Ice Pack

≥ 2 years